Bone Metastasis

Our clinical trial : Bone metastasis

Trial status: recruiting

First posted: 30 January 2023

Last updated: 30 January 2023

 

Full Title

Randomised trial comparing single fraction of proton stereotactic body radiotherapy (SBRT) versus 3 fractions of photon SBRT for bone metastatic patients

Purpose

Due to the accuracy of the proton beam and the paucity of data, treating bone metastases with proton SBRT would be practically challenging. We aim to assess whether proton SBRT can be successfully given to those with bone metastases, and we will compare whether pain control (either complete or partial pain control) is not inferior with proton SBRT in bone metastases patients as compared to photon SBRT.

Eligibility

To be eligible for this study, patients must meet following requirements, including:

  • Patients with a pathologic diagnosis of malignancy
  • Patients who are over 18 years old.
  • Patients with any radiographic evidence of bone metastases, including
    plain x-ray, bone scan, CT scan, MRI scan, or PET scan
  • Patients with a life expectancy of more than 3 months
  • Patients with solitary, oligometastatic, or bone-only metastatic disease
  • Patients who are able to complete the NRPS scores and the questionnaire on quality of life
  • Patients with no more than three separate radiation treatment fields concurrently
  • Patients undergoing surgery for osseous metastases are allowed.
  • Patients with gross residual disease or a high risk for recurrence after surgery 
  • Patients who have already been treated with conventional beam radiation therapy at the treatment site (more than 90 days ago)
  • Patients with spinal cord compression after decompressive surgery

Phase : II/III

Disease Status : Advanced stage (Bone metastatic disease)

Investigator : Kitwadee Saksornchai

Co-Investigators

  • Napapat Amornwichet
  • Kanjana Shotelersak

Diseases : Cancer , bone metastatic disease

Locations : King Chulalongkorn Memorial hospital